The endogenous adrenocortical response to sepsis is critical for host survival. The in vivo interactions among the endogenous glucocorticoid response, the induction of cytokines, and host survival during endotoxemia were explored in this study by use of the glucocorticoid receptor antagonist RU 486. Male Lewis rats underwent sterile insertion of a right jugular venous catheter. After a 72-h recovery period, animals received a 50%370 lethal dose of Escherichia coli endotoxin (2.5 mg/kg) via the catheter after pretreatment for 30 min prior to lipopolysaccharide (LPS) treatment with (i) vehicle alone intravenously (i.v.) (-corticosterone [-Cort]/-RU 486/+LPS) (n = 10), (ii) the antiglucocorticoid RU 486 (10 mg/kg) i.v. (-Cort/+RU 486/+LPS) (n = 11), or (iii) RU 486 (10 mg/kg) i.v. in animals that had undergone subcutaneous implantation of a corticosterone pellet at the time of catheter insertion (+Cort/+RU 486/+LPS) (n = 10). Except in animals receiving corticosterone pretreatment, baseline plasma corticosterone levels were low in all groups. Plasma corticosterone levels increased significantly (P < 0.001) above the baseline following LPS administration. Animals in the -Cort/+RU 486/+LPS-treated group exhibited significantly increased mortality (P < 0.001), with only 9% of the animals surviving at 72 h, as well as significantly increased plasma interleukin-6 levels, compared with animals receiving the vehicle alone (-Cort/-RU 486/+LPS), which showed 50%v mortality. Pretreatment with corticosterone and RU 486 (+Cort/+RU 486/+LPS) significantly (P < 0.001) reversed the mortality observed with RU 486 pretreatment alone (-Cort/+RU 486/+LPS), with 70% of the animals surviving at 72 h, and significantly attenuated the peak plasma tumor necrosis factor and interleukin-6 responses to LPS, compared with those in the animals treated with vehicle alone. These data demonstrate that the blockade of glucocorticoid binding by RU 486 increases LPS-induced mortality. The reversal of this effect by the induction of hypercorticosteronemia prior to RU 486 and LPS exposure (+Cort/+RU 486/+LPS) improves survival and is further associated with significant attenuation of cytokine production. Therefore, these data suggest that the protective effect of the endogenous glucocorticoid response to acute endotoxemia may result from the down-regulation of a potentially lethal cytokine response.
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Bacterial endotoxins have been implicated as a major factor in the pathogenesis of gram-negative septic shock, a clinical problem with significant morbidity and mortality (24) . The induction of cytokine synthesis in response to endotoxin exposure in vivo undoubtedly plays a critical role in the host response to septicemia. Recently, two cytokines, tumor necrosis factor (TNF) and interleukin-6 (IL-6), were implicated as key mediators in this response. Infusion of TNF into laboratory animals elicited physiologic changes similar to those observed in animals with gram-negative septicemia (19, 35, 37) . Furthermore, a role for TNF in the early response to gram-negative sepsis has been suggested by its detection in the circulation of laboratory animals and humans shortly after the administration of endotoxin (12, 22) . Passive immunization of endotoxin-sensitive mice with antiserum to TNF substantially reduced the lethal effects of endotoxin (6) , and pretreatment of baboons (34) and rabbits (21) with a monoclonal antibody to TNF prevented their deaths after the administration of a 100% lethal dose of live Escherichia coli. Similarly, the detection of circulating in both animals and humans shortly after endotoxin administration has also suggested a role for in the early * Corresponding author.
response to gram-negative sepsis (10, 13) . IL-6 has been shown to induce an exuberant acute-phase protein response in vivo after endotoxin exposure (2) . Finally, recent studies have demonstrated that pretreatment of animals with a monoclonal antibody directed against IL-6 is protective against a lethal E. coli infection and a lethal TNF challenge (32) .
The acute protective influence of glucocorticoids against the effects of bacterial endotoxin (lipopolysaccharide [LPS] ) is well established (3, 4, 29, 30) . In experimental models, the protective effect of glucocorticoids against bacterial endotoxin-induced lethality has been well documented (4, 30) , although exogenously administered glucocorticoids in the clinical setting of septicemia and/or shock have produced disappointing results (17, 33 ). An early report by Berry and Smythe demonstrated that the ability of glucocorticoids to protect mice against the lethal effects of LPS was critically dependent on the timing of glucocorticoid administration relative to that of endotoxin challenge (3) . When given either prior to or at the time of LPS administration, glucocorticoids were found to be protective; however, they had no protective effect when given after LPS administration. These findings have been confirmed and extended by others who have demonstrated that adrenalectomy or hypophysectomy markedly sensitizes laboratory animals to the lethal effects of endotoxin (4, 30) . Furthermore, the deleterious effect of adrenalectomy or hypophysectomy on LPS-induced mortality can be abrogated by the administration of exogenous glucocorticoids (4, 30) .
During acute endotoxemia, an early endogenous glucocorticoid response ensues and is generally regarded as essential for host survival. Glucocorticoids have been demonstrated to acutely modulate the production of some cytokines in vitro (5) , whereas the in vivo interaction between glucocorticoid and cytokine host responses to an infectious stimulus (e.g., endotoxin) has not been fully elucidated. A new pharmacologic agent, mifepristone (RU 486), acts as a potent glucocorticoid receptor antagonist (25a), in addition to having a well-described role as an antiprogestational agent (28, 31) . The RU 486 molecule is a synthetic steroid analog whose effects are mediated through competitive binding to the cytoplasmic glucocorticoid receptor. RU 486 acts as a potent antiglucocorticoid both in vitro and in vivo, with a binding affinity equal to or exceeding that of the naturally occurring glucocorticoid agonist in rats and humans, but does not exhibit any agonist activity (14, 20) . In the present study, RU Corticosterone pellet preparation. Corticosterone pellets were prepared in advance by gently heating purified corticosterone (Sigma) until molten. Aliquots of 100 mg were molded into rounded pellets approximately 6 to 7 mm in diameter and allowed to cool and solidify in a nitrogen atmosphere. Prior to recovery of rats from anesthesia, the pellets were implanted in a small subcutaneous pocket in the dorsal surface of the neck. This method has been reported to produce reliable pathophysiologic elevations of plasma corticosterone levels for up to 6 days after implantation (16 Plasma was isolated by centrifugation of whole blood and stored at -70°C until assayed. The animals were neither handled nor manipulated following insertion of the jugular venous catheters for 72 h prior to the initiation of the experiment so as to ensure a relatively "unstressed" state. This "no-touch" model was chosen for this experiment, since previous experiments in our laboratory demonstrated that the mere handling of a rat or the moving of its cage results in significant acute elevations of plasma glucocorticoid levels. The experiment was conducted through four separate runs. The same animals as those used for the measurement of glucocorticoid and cytokine levels as described above were observed for a period of 72 h following endotoxin administration for survival data.
Assays. (i) Plasma corticosterone. Early-morning baseline samples were collected immediately prior to the administration of either RU 486 or LPS. Corticosterone determinations were performed by a direct radioimmunoassay by the method of Keith et al. (18) . This assay had a sensitivity of 16 ng/ml. Plasma samples from adrenalectomized rats served as controls and consistently yielded results below the limit of detection. All samples were assayed together as a group in a single radioimmunoassay.
(ii) Plasma TNF. A WEHI subclone cytotoxicity bioassay was performed to determine plasma TNF activity by the method of Eskandari et al. (8) . In brief, WEHI cells at a concentration of 50,000 cells per well were added to the wells of a 96-well, flat-bottom microtiter plate and allowed to proliferate and adhere over 72 h. At that time, actinomycin D (0.5 ,ug/ml) was added to each well to arrest cell proliferation. Diluted plasma samples to be assayed along with serial dilutions of standard recombinant human TNF (Chiron, Emeryville, Calif.) were added to the wells in triplicate. After incubation overnight, the extent of WEHI cell killing (TNF activity) was quantified by the addition of 3-[4,5 dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (300 ,ug/ml; Sigma) to each well; 4 to 6 h later, the supernatant was removed and the cells were lysed with isopropanol- The activity of the unknown samples was calculated on the basis of the standard curve. Previous studies in our laboratory with neutralizing antibody to TNF have consistently confirmed the specificity of this assay. The sensitivity of this assay was found to be 1 pg/ml.
(iii) Plasma IL-6. A previously described B.9 hybridoma cell proliferation bioassay was used to measure plasma IL-6 activity (1). In brief, 0.1-ml aliquots of the diluted plasma samples were added to flat-bottom, 96-well microtiter plates. Samples were run in duplicate, and three serial dilutions were performed. Purified murine IL-6 (a gift from P. B. Sehgal, Rockefeller University, New York, N.Y.) was used as a standard on each plate. B.9 hybridoma cells at a concentration of 3,500 cells per well were added to the wells and allowed to incubate for 96 h. Proliferation was assessed by a standard colorimetric assay as described above. A standard curve was generated by plotting IL-6 standard concentrations against absorbance values. By linear regression analysis, the activity of the unknown samples was calculated on the basis of the standard curve. The amount of IL-6 capable of inducing one-half maximal proliferation of the B.9 hybridoma cells was defined as 1 U of IL-6. The sensitivity of this assay was found to be 500 U/ml.
Hematocrit and leukocyte determinations. (i) Differential leukocyte counts. Fifty microliters of whole blood was divided into aliquots, and the erythrocytes were lysed by the addition of 950 ,ul of bicarbonate-buffered ammonium chloride solution (Ortho Diagnostic Systems, Raritan, N.J. levels were elevated more than 10-fold (P < 0.01) by 90 min in both the -Cort/-RU 486/+LPS-and the -Cort/+RU 486/+LPS-treated groups and remained significantly elevated throughout the course of the experiment (Fig. 1) . As expected, animals receiving corticosterone-RU 486 pretreatment (+Cort/+RU 486/+LPS) had significantly elevated baseline plasma corticosterone levels (172 ng/ml) prior to LPS exposure, and these levels increased further by 3 to 4 h after LPS exposure (P < 0.01 at the 4-h time point). Corticosterone levels were significantly lower at 90 min after LPS-exposure in this group than in either of the noncorticosterone-pretreated groups (-Cort/-RU 486/+LPS or -Cort/+RU 486/+LPS). In animals not receiving LPS (-Cort/+RU 486/-LPS), plasma corticosterone levels did not change significantly from baseline levels during the course of the experiment (Fig. 1) .
Compared with baseline levels, plasma TNF levels in all three groups receiving an LD50 of LPS reached peak elevations by 1.5 h (Fig. 2A) . In contrast, while plasma IL-6 levels were detectable in all experimental groups by 1.5 h after LPS infusion, these levels continued to rise at 3 to 4 h after LPS infusion (Fig. 2B) (Fig. 2B ) at 3 h after LPS infusion; however, no significant changes in the TNF profile were observed in the group treated with the RU 486 alone (-Cort/ +RU 486/+LPS) ( Fig. 2A) . Plasma IL-6 concentrations in the -Cort/-RU 486/+LPS-treated group were intermediate between those in the other two groups (Fig. 2B) . By 3 h after LPS infusion, although still elevated, TNF levels had returned to baseline levels in all three groups (Fig. 2A) . Plasma TNF or IL-6 was not detectable at any time point ( Fig. 2A   and B) nt (+Cort/+RU h after LPS administration (Fig. 3) . In contrast, animals Cort/-RU 486/ pretreated with corticosterone (+Cort/+RU 486/+LPS) exetreatment with hibited significantly improved survival compared with ani-)n (-Cort/+RU mals in either of the non-corticosterone-pretreated groups ition (2.5 mg/kg (-Cort/+RU 486/+LPS or -Cort/-RU 486/+LPS), with Cort/+RU 486/ 70% surviving at 72 h (Fig. 3) . The mortality observed in all )f a corticoster-groups occurred relatively early in the course of endotoxit (+Cort/+RU emia, usually within 12 h following LPS administration. All RU 486/+LPS-of the animals in the control group, receiving only RU 486 1.01 versus the without subsequent LPS administration (-Cort/+RU 486/ -LPS), survived (Fig. 3 ). All groups were significantly (P < 0.01; log rank statistic) different from one another.
DISCUSSION
In the present investigation, we demonstrated that the blockade of glucocorticoid receptors increased LPS-induced mortality. Additionally, mortality in the RU 486-pretreated animals (-Cort/+RU 486/+LPS) was of significantly greater magnitude than mortality in the animals pretreated with either the vehicle alone (-Cort/-RU 486/+LPS) or corticosterone (+Cort/+RU 486/+LPS). Also, elevation of plasma corticosterone to levels comparable to those measured following severe injury (+Cort/+RU 486/+LPS) reversed the increased mortality observed with RU 486 pretreatment (-Cort/+RU 486/+LPS), a finding consistent with previous studies in which glucocorticoid pretreatment could reverse, at least in part, the increased LPS-induced mortality in adrenalectomized or hypophysectomized animals (4, 30) .
No effect on the endogenous glucocorticoid response to endotoxemia was seen as a result of RU 486 pretreatment in this model. In addition, despite pretreatment with corticosterone for 72 h prior to LPS administration, a significant rise in the plasma corticosterone level (4 h) after LPS administration was observed, albeit with a delayed time course. This delayed glucocorticoid response to LPS challenge in the corticosterone-pretreated animals likely resulted from negative feedback inhibition by the exogenously administered corticosterone. However, the ability to mount a significant endogenous glucocorticoid response to endotoxemia above the levels achieved by exogenous pretreatment with corticosterone suggests (i) the preservation of adrenal glucocorticoid secretory capacity in response to an appropriate challenge and (ii) the ability of LPS and/or LPS-induced mediators to acutely overcome any feedback inhibition of adrenocorticotropin secretion, perhaps through a direct effect on the hypothalamus. The failure of RU 486 pretreatment to overcome the protective glucocorticoid effect in the corticosterone-pretreated animals (+Cort/+RU 486/+LPS) suggested temporally advanced glucocorticoid "priming" of glucocorticoid-responsive cells, rendering them insensitive to subsequent RU 486 exposure.
Although protection against LPS-induced mortality through a glucocorticoid-related mechanism has been demonstrated in this model and others (3, 4, 30, 38) (30) . Finally, it has also been shown that the infusion of pharmacological doses of cortisol into normal human volunteers prior to LPS administration results in a diminished appearance of TNF in the circulation as well as an attenuation of the clinical signs and symptoms of endotoxemia (la).
In this study, glucocorticoid pretreatment (+Cort/+RU 486/+LPS) significantly attenuated the release of both IL-6 and TNF in response to LPS challenge, while pretreatment with the antiglucocorticoid RU 486 (-Cort/+RU 486/+LPS) resulted in an increase in the levels of circulating IL-6 but not TNF. This disparity in the circulating IL-6 and TNF responses to LPS is intriguing and may be due, in part, to a relative lack of glucocorticoid influence on the initial TNF response to LPS. As previously shown, elevated plasma TNF levels are correlated with increased mortality (35) . In the present study, plasma TNF levels peaked at 1.5 h and returned to baseline levels by 3 h after LPS administration, while plasma IL-6 levels peaked at 4 h after LPS administration. Differences in mortality between groups, however, did not begin to become apparent until at least 4 h after LPS administration. The temporal association between peak plasma TNF levels at 1.5 h and differences in mortality between groups at 4 h after LPS administration suggests that TNF may have a critical role in the observed differences in mortality, at least in the corticosterone-pretreated group (+Cort/+RU 486/+LPS). However, the increased mortality observed in the RU 486-pretreated group (-Cort/+RU 486/ +LPS) and the lack of a significant change in plasma TNF levels following endotoxin administration in this group suggest that perhaps other mediators, such as IL-6, which was elevated to the greatest extent in this group, may be involved in the observed increased mortality. Although increased plasma IL-6 levels are consistently observed to correlate with mortality in clinical studies and animal models (15, 32, 36) , such a correlation does not provide evidence that this cytokine is the ultimate mediator of LPS-induced tissue injury or mortality. In fact, exogenous IL-6 administration does not replicate the tissue injury and mortality observed with LPS administration in experimental animals (26 (25, 27) . The baseline leukocyte count following pretreatment with corticosterone (+Cort/+RU 486/+LPS) was significantly lower than the baseline leukocyte counts in the other groups. This low baseline count can be accounted for almost entirely by a decrease in the numbers of mononuclear leukocytes (i.e., lymphocytes and monocytes), whose numbers have been shown previously to decline in the presence of elevated circulating glucocorticoids (9 (11) .
Although the present study and other studies (3, 4, 30) point to a protective role of glucocorticoids in acute, lethal endotoxemia, such may not be the case in chronic gramnegative infections. In the latter situation, a sustained elevation of glucocorticoid levels may suppress the development of specific immunity (7) to the invading microorganism(s), resulting in delayed bacterial clearance or actual progression of an otherwise controllable infection.
These findings and those of others suggest a critical role for an intact endogenous glucocorticoid response to endotoxemia in the protection of the host from LPS-induced mortality. It was further demonstrated that RU 486 pretreatment augments IL-6 production, while corticosterone pretreatment significantly attenuates the appearance of both IL-6 and TNF in the circulation in response to endotoxemia. Therefore, it appears that the protective effect of the endogenous glucocorticoid response to endotoxemia may result from the down-regulation of a potentially lethal cytokine response to LPS. The data further suggest a complex, dynamic interaction between glucocorticoid activity and regulation of the cytokine cascade.
